Equities analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will announce earnings of ($0.43) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Nektar Therapeutics’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.11). Nektar Therapeutics reported earnings of ($0.42) per share in the same quarter last year, which indicates a negative year over year growth rate of 2.4%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($2.16) to ($0.51). For the next year, analysts anticipate that the company will post earnings of ($1.41) per share, with EPS estimates ranging from ($3.64) to $0.99. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.14. Nektar Therapeutics had a negative return on equity of 156.85% and a negative net margin of 31.42%. The firm had revenue of $95.47 million during the quarter, compared to the consensus estimate of $36.96 million. During the same period last year, the business posted ($0.28) EPS. The business’s revenue was up 154.9% compared to the same quarter last year.
A number of analysts have weighed in on the company. HC Wainwright set a $125.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday. Mizuho increased their price target on Nektar Therapeutics from $89.00 to $103.00 and gave the stock a “buy” rating in a report on Friday. BidaskClub upgraded Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 21st. Cowen reiterated a “buy” rating and set a $101.00 price target on shares of Nektar Therapeutics in a report on Friday, March 2nd. Finally, Jefferies Group increased their price target on Nektar Therapeutics to $103.00 and gave the stock a “buy” rating in a report on Friday, March 2nd. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $63.75.
In other news, SVP Stephen K. Doberstein sold 2,426 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $201,212.44. Following the transaction, the senior vice president now owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO John Nicholson sold 4,879 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $82.94, for a total transaction of $404,664.26. Following the transaction, the chief operating officer now directly owns 387,657 shares in the company, valued at approximately $32,152,271.58. The disclosure for this sale can be found here. Insiders have sold a total of 369,592 shares of company stock worth $34,241,981 in the last three months. Insiders own 5.44% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in NKTR. BB&T Investment Services Inc. bought a new position in shares of Nektar Therapeutics during the 4th quarter worth about $119,000. Meeder Asset Management Inc. bought a new position in shares of Nektar Therapeutics during the 4th quarter worth about $121,000. Oppenheimer Asset Management Inc. bought a new position in shares of Nektar Therapeutics during the 3rd quarter worth about $129,000. Certified Advisory Corp bought a new position in shares of Nektar Therapeutics during the 4th quarter worth about $148,000. Finally, SeaCrest Wealth Management LLC bought a new position in shares of Nektar Therapeutics during the 4th quarter worth about $200,000. 96.22% of the stock is currently owned by institutional investors.
Nektar Therapeutics stock traded up $10.58 during trading hours on Monday, reaching $104.45. 2,857,531 shares of the company’s stock were exchanged, compared to its average volume of 3,136,327. The company has a current ratio of 5.82, a quick ratio of 5.63 and a debt-to-equity ratio of 2.79. Nektar Therapeutics has a twelve month low of $17.33 and a twelve month high of $111.36. The company has a market cap of $15,105.83, a P/E ratio of -189.91 and a beta of 1.73.
TRADEMARK VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/09/0-43-earnings-per-share-expected-for-nektar-therapeutics-nktr-this-quarter.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.